Skye Bioscience, Inc. Lessee, Operating Lease, Liability, to be Paid, Year One
Skye Bioscience, Inc. (SKYE) had Lessee, Operating Lease, Liability, to be Paid, Year One of $215.13 thousand as of 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2025-03-20
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $215.13K.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $103.22K.
- 2023-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $103.22K.
- 2023-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $103.22K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2024-12-31 | $215.13K 10-K · filed 2025-03-20 |
| 2023-12-31 | $103.22K 10-K · filed 2024-03-22 |
| 2023-09-30 | $103.22K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $103.22K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $83.58K 10-Q · filed 2023-05-12 |
| 2022-09-30 | $83.09K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $83.09K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $83.09K 10-Q · filed 2022-05-06 |
| 2021-12-31 | $97.29K 10-K · filed 2022-03-28 |
| 2021-09-30 | $97.29K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |